Jonathan Chang
Stock Analyst at Leerink Partners
(0.64)
# 3,756
Out of 4,754 analysts
92
Total ratings
30.14%
Success rate
-19.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Upgrades: Outperform | $27 | $22.68 | +19.05% | 10 | Feb 13, 2025 | |
| VINC Vincerx Pharma | Maintains: Outperform | $80 → $40 | $1.09 | +3,569.72% | 6 | Oct 8, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $29.37 | +151.96% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $3.51 | +213.39% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $19.07 | +167.44% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $7.95 | +843.40% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $12.68 | +168.14% | 9 | Dec 7, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $10.97 | +355.79% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $40.74 | -26.36% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $2.46 | +387.80% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $0.52 | +2,574.82% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $4.38 | +493.61% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $34.64 | +174.25% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.54 | +455.56% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $7.71 | +263.16% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $15.36 | +245.05% | 7 | Aug 5, 2021 |
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $22.68
Upside: +19.05%
Vincerx Pharma
Oct 8, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $1.09
Upside: +3,569.72%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $29.37
Upside: +151.96%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $3.51
Upside: +213.39%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $19.07
Upside: +167.44%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $7.95
Upside: +843.40%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $12.68
Upside: +168.14%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $10.97
Upside: +355.79%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $40.74
Upside: -26.36%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $2.46
Upside: +387.80%
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $0.52
Upside: +2,574.82%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $4.38
Upside: +493.61%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $34.64
Upside: +174.25%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.54
Upside: +455.56%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $7.71
Upside: +263.16%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $15.36
Upside: +245.05%